论文部分内容阅读
目的 :检测膀胱癌组织中 nm2 3和 p53基因外显子突变情况 ,寻找有助于准确预测局部肿瘤进展、分型、预后情况的临床参照指标。 方法 :应用 PCR- SSCP检测 2 8例膀胱癌术后存档蜡块组织中nm2 3及 p53基因外显子突变情况 ,并与膀胱癌的病理及临床指标进行相关性研究。结果 :nm2 3及 p53基因突变率分别为 1 4.3%及 1 7.99%。nm2 3及 p53基因突变均发生在低分化组及有淋巴结转移病例。nm2 3和/或 p53基因突变与 UICC临床分期和淋巴结转移均呈正相关 ( P<0 .0 1 )。结论 :nm2 3和 /或 p53基因突变与膀胱癌恶性程度进展有关 ,与肿瘤淋巴结转移有密切关系。 nm2 3及 p53基因突变在判断膀胱癌细胞增殖、分化程度、恶性进度及预后转归方面有一定价值 ,可作为判断膀胱癌预后的参考指标 ,指导高危患者的进一步治疗。
OBJECTIVE: To detect the mutations of nm23 and p53 exon in bladder cancer tissues, and to find out the clinical reference indexes that can help predict the local tumor progression, classification and prognosis accurately. Methods: PCR-SSCP was used to detect the exon mutations of nm23 and p53 gene in 28 paraffin-embedded tissues of bladder cancer after operation. The correlation was analyzed with the pathological and clinical indexes of bladder cancer. Results: The mutation rates of nm23 and p53 were respectively 1.43% and 17.99%. nm23 and p53 gene mutations occurred in poorly differentiated and lymph node metastasis cases. The mutation of nm23 and / or p53 was positively correlated with clinical stage and lymph node metastasis of UICC (P <0.01). Conclusion: The mutation of nm23 and / or p53 is associated with the malignant degree of bladder cancer and closely related to the metastasis of tumor. The mutation of nm23 and p53 has some value in judging the proliferation, differentiation, malignancy and prognosis of bladder cancer cells, which can be used as a reference index to judge the prognosis of bladder cancer and guide the further treatment of high-risk patients.